Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Heparin Anti-Xa Monitoring in Microvascular Surgery
NCT02970032Phase 1Completed
- Sponsor
- University of Utah
- Start
- Nov 2016
- Primary completion
- Sep 2017
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of heparin in venous thromboembolism (VTE) (2 arms), sponsored by University of Utah. Primary endpoint: Number of Participants With Anti-Xa Levels Within Target Range (0.1-0.35 IU/mL). Started Nov 2016; status: completed.
02
Drugs
heparin
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT02970032.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02970032.